In the scope of medical devices and biopharmaceuticals, Flen Health stands as a groundbreaking force with a mission to revolutionize wound healing solutions. With a deep commitment to innovation, Flen Health has not only earned a remarkable reputation in the wound care and skin healing industry but has also managed to thrive within the nurturing ecosystem of the House of BioHealth. In this exclusive interview, we delve into the world of Flen Health with insights from Frédérique Sine, the HR Manager, and Claire Barbieux, the R&D Manager.


Flen Health’s Remarkable Journey

Flen Health, founded in 2000 in Belgium, has come a long way since its inception. According to Frédérique Sine, the HR Manager at Flen Health, the company has expanded its presence across Europe and its products are now distributed in over 30 countries worldwide. This exponential growth is a testament to their unwavering dedication to providing effective wound-healing solutions.


Innovative wound healing solutions

Claire Barbieux, the R&D Manager at Flen Health, highlights the company’s commitment to innovation. Flen Health is renowned for its flagship products, Flamigel® and Flaminal®. Flamigel®, an innovative gel, not only accelerates wound healing but also reduces the risk of scarring. On the other hand, Flaminal® (Hydro / Forte) is a versatile product that caters to acute and chronic wound types, providing specialized solutions for different levels of wound exudate. The wound treatment is available in two formulations: Flaminal® Hydro for slightly to moderately exuding wounds and Flaminal® Forte for wounds with moderate to high amounts of wound exudate.


Biopharmaceutical aspirations

While Flen Health is deeply rooted in the medical devices sector, it is currently undergoing a transformation to become a significant player in the biopharmaceutical industry. The company’s vision is to maximize its objective of providing innovative wound healing solutions via a well-balanced portfolio in research, development and registered and launched products to support its market-leading position across various regions.


Innovation at the core

One of Flen Health’s most recent innovations is a technology platform developed by its R&D team. This platform can mimic the in vitro wound environment, a crucial step in understanding and addressing the complexities associated with poor wound healing outcomes. This innovation reflects Flen Health’s solid commitment to advancing wound care.


House of BioHealth: a catalyst for growth

The House of BioHealth (HoBH) has played a pivotal role in Flen Health’s evolution. According to Frédérique Sine, Flen Health has been a part of HoBH since its first building was established in 2015. This collaboration has been instrumental in fostering connections with industry peers, partners, and specialists. The networking opportunities and events hosted at HoBH have facilitated meaningful collaborations, allowing Flen Health to tap into the expertise of the healthcare community.

Claire Barbieux underscores the advantages of being part of HoBH, highlighting the invaluable partnerships they have forged with other companies in the health sector. These partnerships have enabled Flen Health to access state-of-the-art facilities to conduct their cutting-edge R&D activities, further driving their commitment to innovation and excellence in wound healing solutions.